Advanced cervical cancer treatment: where immunotherapy and cadonilimab fit

Clarify what advanced means in your diagnosis

Locally advanced cervical cancer may still be treated with a curative radiation-based approach. Metastatic disease or a recurrence after previous treatment raises different questions about systemic therapy and selected local interventions. Ask the team to explain the current stage and the goal of the proposed course.

Bring the pathology, imaging and complete previous radiation and medicine records. If a recurrence is suspected, ask what confirms it and whether it is confined to one area. Those facts affect whether the main discussion is further local treatment, systemic therapy or a combination.

Sources and references: [1] [2]

Keep brachytherapy visible in a radiation-based plan

For many patients with locally advanced cervical cancer, treatment combines external-beam radiation, chemotherapy and brachytherapy. Brachytherapy delivers radiation close to the cervical tumor and is an important component of the treatment discussion.

Pembrolizumab has a US approval with chemoradiotherapy for FIGO 2014 stage III-IVA disease. If immunotherapy is proposed, ask how it fits with the full radiation schedule, including brachytherapy, and how the staging system applies to you. Confirm the local indication when comparing treatment in another country.

Sources and references: [1] [3]

Discuss systemic therapy in recurrent or metastatic disease

For persistent, recurrent or metastatic cervical cancer, systemic options may include chemotherapy, an immune checkpoint inhibitor and, when appropriate, bevacizumab. The decision accounts for previous platinum treatment, PD-L1 results, the pattern of recurrence and overall condition.

Ask whether PD-L1 has been tested and which scoring method appears in the report. Some regimens have a PD-L1 requirement and others address a broader group. A negative result is therefore a reason to compare the actual indications carefully and identify the options that fit.

Sources and references: [2] [4]

Where cadonilimab is approved in China

Cadonilimab is a bispecific antibody that targets PD-1 and CTLA-4. China has approved it with platinum-based chemotherapy, with or without bevacizumab, for first-line treatment of persistent, recurrent or metastatic cervical cancer. It also has a Chinese indication after progression during or following platinum chemotherapy in recurrent or metastatic disease.

The COMPASSION-16 phase 3 study supports the first-line combination and included patients across PD-L1 groups. If cadonilimab is being considered, ask which treatment line applies to you, whether bevacizumab is suitable and how the combination compares with your other available options.

Sources and references: [4] [5]

Understand why bevacizumab may be included or omitted

Bevacizumab acts on blood-vessel growth and may be part of an advanced-disease regimen. Its suitability depends on issues such as blood pressure, bleeding, wound healing and fistula risk. Previous pelvic radiation and current bowel or bladder involvement are relevant to the assessment.

Tell the team about bleeding, drainage, infections, recent operations and any passage of urine or stool through an unusual route. Ask why bevacizumab is recommended or omitted in your case. The answer should connect the potential benefit with your anatomy and treatment history.

Sources and references: [2]

Know which symptoms need early attention

Immune treatments can cause inflammation in organs such as the bowel, lungs, liver and hormone-producing glands. New persistent diarrhea, breathlessness, yellowing of the skin or severe unexplained fatigue should be reported promptly. These effects need a different assessment from routine chemotherapy nausea.

Ask for a written contact plan and a list of the medicines in your regimen. Discuss autoimmune disease, organ transplantation and medicines that suppress immunity before treatment. If you receive care away from your oncology center, show the emergency team that immunotherapy is part of your treatment.

Sources and references: [6]

Address pain, bleeding and practical recovery needs

Pain, fatigue, anemia, urinary obstruction and nutritional problems can affect treatment tolerance. Ask which symptoms need a separate local intervention or supportive-care appointment. Heavy bleeding, fever or rapidly worsening pain needs prompt assessment rather than waiting for the next planned infusion.

Sexual health, menopausal symptoms and emotional distress also deserve a place in follow-up. If radiation is part of your care, request advice tailored to the treatment field and healing stage. For international treatment, decide who will arrange blood tests and symptom care once you return home.

Sources and references: [2] [1]

Prepare a complete gynecologic oncology review

Fudan University Shanghai Cancer Center has gynecologic oncology and radiation oncology services. A useful consultation can clarify the disease setting, review the complete radiation plan or compare systemic regimens, including whether a China-approved option is relevant.

Send EastMedGo the pathology, imaging, PD-L1 result, previous radiation planning files and treatment dates. Include current bleeding, bowel or bladder symptoms. We can organize the case for a focused consultation request and help coordinate the next records, appointment and treatment-planning steps.

Sources and references: [7]

Common questions